Orchestra BioMed (NASDAQ:OBIO – Get Free Report) and Beyond Air (NASDAQ:XAIR – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.
Earnings & Valuation
This table compares Orchestra BioMed and Beyond Air”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Orchestra BioMed | $33.48 million | 10.03 | -$52.70 million | ($0.85) | -6.58 |
| Beyond Air | $7.68 million | 0.26 | -$33.25 million | ($68.40) | -0.03 |
Beyond Air has lower revenue, but higher earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 31.5% of Beyond Air shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by insiders. Comparatively, 10.0% of Beyond Air shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Orchestra BioMed and Beyond Air’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Orchestra BioMed | -184.60% | -149.61% | -54.15% |
| Beyond Air | -435.71% | -440.26% | -98.50% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Orchestra BioMed and Beyond Air, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Orchestra BioMed | 1 | 0 | 6 | 0 | 2.71 |
| Beyond Air | 1 | 0 | 3 | 0 | 2.50 |
Orchestra BioMed currently has a consensus target price of $13.17, indicating a potential upside of 135.54%. Beyond Air has a consensus target price of $105.00, indicating a potential upside of 4,923.92%. Given Beyond Air’s higher possible upside, analysts clearly believe Beyond Air is more favorable than Orchestra BioMed.
Risk & Volatility
Orchestra BioMed has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Beyond Air has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.
Summary
Orchestra BioMed beats Beyond Air on 10 of the 14 factors compared between the two stocks.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
About Beyond Air
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
